Molecular diagnostics has long been the fastest growing branch in the field of in vitro diagnostics. Excluding the epidemic factors, the global molecular diagnostics market will exceed US$10 billion in 2022.

ꔷ  China's molecular diagnostics industry is still in its infancy. Excluding the factors of the epidemic, the industry's average CAGR has exceeded 30% in the past five years, but the per capita molecular diagnostics consumption is only one-third of the world average.

ꔷ  There are more than 5,000 genetic and infectious diseases for which there are no effective clinical diagnostic tools.

ꔷ  Molecular diagnosis is the foundation of precision medicine. In the next five years, more than 100 new targeted drugs are expected to enter clinical practice around the world.

ꔷ  Molecular diagnosis is one of the most powerful weapons for mankind to respond to public health emergencies such as the COVID-19 epidemic.

Embrace the future and lead a new era of molecular diagnosis

Pregene Biotech is an innovative biotechnology enterprise with full-chain independent innovation technology as its core and integrating next-generation molecular diagnostic instruments, reagents, and medical testing services. The company has a number of national and international patents and is a leading provider of research and development covering tumor diagnosis, infection detection, A provider of NeoHiT® PCR clinical diagnostic solutions in the three major fields of reproductive health.

ꔷ  Pregene Biotechnology is the global pioneer of NeoHiT® PCR technology. Based on unmet clinical needs, it innovates the underlying technology platform and innovatively develops a NeoHiT® PCR system (including NeoHiT® PCR technology and fluorescence encoding technology); breaking through traditional PCR detection Signal level, it has the dual advantages of large amount of detection information and high detection sensitivity, solving the long-term pain points of the molecular diagnostic industry; creating a "more, faster, better and more economical" next-generation molecular diagnostic platform, which can easily, quickly and economically realize the complex equipment that was originally required Clinical applications can be completed to support IVD admissions and popularization.

ꔷ  The company was founded by a team of returnee scientists. The core team has comprehensive backgrounds in management, R&D, registration, clinical and sales. Most of the team members come from key universities at home and abroad, with nearly 70% of them having master's and doctoral degrees. The company is headquartered in a top-notch high-end medical device company in China. The new drug production base - Nanjing Jiangbei New District Biomedicine Valley, covers an area of ​​nearly 8,000 square meters, of which 4,000 square meters are GMP standardized factory buildings.

ꔷ  Adhering to the concept of "innovation, making health accurate and accessible", Pregene Biotech focuses on unmet needs in the clinical field, and promotes the development of molecular diagnostic technologies that benefit everyone on a global scale through disruptive underlying research and innovation; Through continuous product innovation and service upgrades, we will become the world's leading provider of molecular diagnostic solutions and contribute more to the health and well-being of people around the world.